M161 M161 (Didanosine Delayed Release 250 mg)
Pill with imprint M161 M161 is Yellow, Capsule-shape and has been identified as Didanosine Delayed Release 250 mg. It is supplied by Mylan Pharmaceuticals Inc..
Didanosine is used in the treatment of hiv infection; nonoccupational exposure and belongs to the drug class nucleoside reverse transcriptase inhibitors (NRTIs). There is no proven risk in humans during pregnancy. Didanosine 250 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for M161 M161
Didanosine Delayed Release
- Imprint
- M161 M161
- Strength
- 250 mg
- Color
- Yellow
- Size
- 21.00 mm
- Shape
- Capsule-shape
- Availability
- Prescription only
- Drug Class
- Nucleoside reverse transcriptase inhibitors (NRTIs)
- Pregnancy Category
- B - No proven risk in humans
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Mylan Pharmaceuticals Inc.
- National Drug Code (NDC)
- 00378-8888
- Inactive Ingredients
-
ferrosoferric oxide, carboxymethylcellulose sodium, silicon dioxide, diethyl phthalate, gelatin, hypromelloses, methacrylic acid - methyl methacrylate copolymer (1:1), propylene glycol, ferric oxide red, shellac, trisodium citrate dihydrate, sodium lauryl sulfate, sodium starch glycolate type A potato, magnesium silicate, titanium dioxide, ferric oxide yellow, potassium hydroxide, ammonia
Note: Inactive ingredients may vary.
Related Images for "M161 M161"
More about didanosine
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: nucleoside reverse transcriptase inhibitors (NRTIs)
- FDA Alerts (2)
Consumer resources
- Didanosine
- Didanosine (Advanced Reading)
- Didanosine Delayed-Release Enteric-Coated Capsules
- Didanosine Oral Solution
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
